Hamzah Syed

8PUBLICATIONS
19CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEmergency medicineStochastic analysis and modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 08, 2025
Epidrug screening identifies type I PRMT inhibitors as modulators of lysosomal exocytosis and drug sensitivity in cancers.

Baris Sergi, Neslihan Yuksel-Catal, Selahattin Can Ozcan

|Jul 18, 2025
Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancer.

Buse Cevatemre, Arda Işiklar, İpek Bulut

|Jun 29, 2025
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer.

Ozlem Yedier-Bayram, Ahmet Cingöz, Ebru Yilmaz

|Feb 12, 2024
Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.

Buse Cevatemre, Ipek Bulut, Beyza Dedeoglu

|Aug 16, 2022
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.

Ozlem Yedier-Bayram, Bengul Gokbayrak, Alisan Kayabolen

|Aug 27, 2021
Design and Adoption of Low-Cost Point-of-Care Diagnostic Devices: Syrian Case.

M Munzer Alseed, Hamzah Syed, Mehmet Cengiz Onbasli

Pageof 2

Frequent Collaborators

4 joint publications

Ceyda Acilan

3 joint publications

Tugba Bagci-Onder

2 joint publications

Tamer T Onder

2 joint publications

Ceyda Acilan